Xtrackers S&P Europe ex UK UCITS ETF (GB:XUEK) Price & Chart

GB:XUEK ETF Chart & Stats

£7,638.50

At close: Nov 10 4:00 PM EST

Day’s Range: GBP 7,635.50 - GBP 7,677.00
52-Week Range: GBP 6,660.00 - GBP 8,018.00
Previous Close: GBP 7,578.00
Volume: 4,802
Average Volume (3M): 8,253
AUM: 527.49M
NAV: 91.22
Expense Ratio: 0.09%
Holdings Count: 311
Beta: 0.91
Inception Date: Jan 14, 2019
Last Dividend Ex-Date: Nov 18, 2026
Dividend Yield: (2.41%)
Shares Outstanding: 5,969,374
Standard Deviation: N/A

ETF Overview

Xtrackers S&P Europe ex UK UCITS ETF

The Xtrackers S&P Europe ex UK UCITS ETF, trading under the ticker GB:XUEK, offers investors a strategic gateway to capture the dynamic potential of European markets, excluding the UK. This ETF is meticulously designed to mirror the performance of the S&P Europe ex UK Index, providing a comprehensive exposure to a diverse array of large, mid, and small-cap companies across developed European nations. With a focus on the Total Market category, this fund is an ideal choice for investors seeking a balanced and diversified portfolio within the broad-based niche of European equities. By excluding the UK, the fund allows for concentrated investment opportunities in continental Europe, potentially reducing the impact of UK-specific market volatility. It's a robust vehicle for those aiming to harness growth from Europe's economic heartbeat, all while benefiting from the cost-efficiency and transparency synonymous with UCITS ETFs. Whether you are an institutional investor or an individual looking to diversify your portfolio, GB:XUEK provides a sophisticated and efficient means to access Europe's diverse market landscape.

GB:XUEK ETF News

Midday Fly By: CoreWeave reports beat and raise, OpenAI revenue jumps 50% in Q3

The major averages were higher near noon, led by a big rebound in the Nasdaq as a better-than-expected quarterly report from CoreWeave helped ease concerns around the sustainability of AI

7h agoC DB

Goldman, Citi, banks commit $270M for joint stablecoin, Bloomberg says

Goldman Sachs (GS), Citigroup (C), Banco Santander (SAN), and Deutsche Bank (DB) are among the financial firms that have committed $270M in funding toward a joint stablecoin venture, Anna Irrera

12h agoC DB

Novartis presents long-term results from ongoing NEPTUNUS extension study

Novartis (NVS) presented long-term results from the ongoing NEPTUNUS extension study of ianalumab in Sjogren’s disease at the American College of Rheumatology Convergence 2026. The data showed that the reduction

1d agoNVS NOT

TotalEnergies Declares Purchases of 2,440,969 Own Shares

An announcement from TotalEnergies SE ( ($FR:TTE) ) is now available. TotalEnergies SE declared that it purchased 2,440,969 of its own shares for €199,999,851.21 between November 2 and November 6,

1d agoTTE TOT

0P6M Upcoming Earnings Report: What to Expect?

Siemens Ag (UK) (0P6M) is scheduled to report 4th quarter earnings on 11/12/2026, before the market opens. Regarding Q4 estimates, Wall Street analysts expect Siemens Ag (UK) to post earnings

1d agoSIE 0P6M

0M6S Earnings this Week: How Will it Perform?

Allianz SE (UK) (0M6S) is scheduled to report 3rd quarter earnings on 11/12/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Allianz SE (UK) to post earnings

1d agoALV 0M6S

Banco Santander (SAN) Shareholder Investigation: Banking on Growth? Quarterly Results Raise Questions About Financial Expectations

Levi & Korsinsky notifies investors that it has commenced an investigation of Banco Santander, S.A. (Banco Santander, S.A.) (NYSE:SAN) concerning possible violations of federal securities laws. Banco Santander, S.A. shares

2d agoSAN BCDRF

Roche price target raised to CHF 440 from CHF 400 at Citi

Citi raised the firm’s price target on Roche (RHHBY) to CHF 440 from CHF 400 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate

2d agoCHRO ROP

FDA warns of NAION vision loss risk with GLP-1 RA drugs

The Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy associated with use of glucagon-like peptide-1 receptor

2d agoLLY NVS

Iberdrola upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Robert Pulleyn upgraded Iberdrola (IBDRY) to Overweight from Equal Weight with a EUR 26 price target Published first on TheFly – the ultimate source for real-time, market-moving

2d agoIBE IBDRY

SAP upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded SAP (SAP) to Overweight from Neutral with a price target of EUR 275, up from EUR 175, implying 30% upside. The firm says AI moving from pilot to

2d agoSAP SAPA

Weekend Fly By: Top five stock stories

Catch up on the weekend’s top five stories with this list compiled by The Fly: Nvidia (NVDA) said in a statement that its board is “initiating an independent investigation in

2d agoANT NVS

Novartis to discontinue development of pelacarsen, Bloomberg says

Novartis (NVS) is discontinuing the development of pelacarsen, a drug that was meant to treat atherosclerotic cardiovascular disease, Fabienne Kinzelmann and Robert Langreth of Bloomberg reports. The move comes after

3d agoNVS NOT

Odds On: Want to bet on if the AI bubble bursts?

“Odds On” is The Fly’s weekly series diving into the most interesting bets on events trading platforms like Polymarket, Kalshi, and Robinhood. Subscribers, add $EBET to your Fly portfolios for

5d agoSPY TSM

See More GB:XUEK News

GB:XUEK ETF FAQ

What was GB:XUEK’s price range in the past 12 months?

GB:XUEK’s lowest price in the past 12 months was GBP 6,660.00 and its highest was GBP 8,018.00.

What is the AUM of GB:XUEK?

As of Nov 10, 2026, the AUM of GB:XUEK is £527.49M.

Is GB:XUEK overvalued?

Based on Wall Street analyst price targets for GB:XUEK’s holdings, GB:XUEK’s price is currently undervalued.

Does GB:XUEK pay dividends?

Yes. GB:XUEK pays dividends quarterly. Its most recent dividend was £16.49 per share, and its annual dividend yield is 2.41%. See more information on GB:XUEK dividends here.

How many shares outstanding does GB:XUEK have?

GB:XUEK has 5,969,374 shares outstanding.

Top 10 Holdings

The fund's ten largest positions
Name	Weight %
ASMLASML Holding NV	5.10%
ROPRoche Holding	3.17%
NOVNNovartis	2.83%
NESNNestlé	2.59%
SAPSAP SE	2.32%
SIESiemens Ag (UK)	2.07%
ALVAllianz SE (UK)	1.86%
TTETotalEnergies SE	1.73%
SANBanco Santander SA	1.72%
IBEIberdrola SA (UK)	1.44%
Total	24.84%

See All Holdings

Popular ETFs

Popular ETFs
Company	Price & Change	Follow
SPYSPDR S&P 500 ETF Trust
QQQInvesco QQQ Trust
DIASPDR Dow Jones Industrial Average ETF Trust
IWMiShares Russell 2000 ETF
VOOVanguard S&P 500 ETF